Davis Polk & Wardwell LLP (LexBlog Russia)

4 results for Davis Polk & Wardwell LLP (LexBlog Russia)

  • Davis Polk Client Memorandum: Second Round of Sanctions on the Russian Federation under Chemical and Biological Weapons Control and Warfare Elimination Act

    On August 3, 2019, the U.S. Department of State and the Department of the Treasury announced a second round of sanctions on the Russian Federation pursuant to the Chemical and Biological Weapons Control and Warfare Elimination Act of 1991 (CBW Act) in response to Russia’s involvement in a chemical weapons attack in the United Kingdom...

  • Russia Sanctions Updates

    The past two weeks have seen a number of developments with respect to U.S. sanctions relating to Russia, as the Trump administration has (1) taken additional steps to ameliorate adverse consequences for U.S. persons of the significant sanctions actions targeting Russian oligarchs announced on April 6, 2018; (2) further implemented the Russia-related sanctions provisions of...

  • OFAC Further Expands, Extends, Russia-related General Licenses

    The Department of the Treasury’s Office of Foreign Assets Control (“OFAC”) has recently issued several new or amended Ukraine-/Russia-related General Licenses (“GLs”) and corresponding guidance related to the ongoing maintenance or wind down of certain activities involving GAZ Group and other blocked persons, and divestment of debt, equity, and other holdings in certain entities.  These...

  • Teva Pharmaceuticals to Pay $519 Million in FCPA Resolution

    On December 22, 2016, Teva Pharmaceutical Industries Ltd. entered into a deferred prosecution agreement and its wholly owned Russian subsidiary Teva LLC agreed to plead guilty to conspiracy to violate the FCPA for a scheme to bribe government officials in Russia, Ukraine, and Mexico.  Between 2006 and at least 2012, Teva made corrupt payments to...

  • Request a trial to view additional results

VLEX uses login cookies to provide you with a better browsing experience. If you click on 'Accept' or continue browsing this site we consider that you accept our cookie policy. ACCEPT